Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 28% ± 10% | |
endothelial cell of lymphatic vessel | 12 studies | 28% ± 8% | |
mesothelial cell | 9 studies | 37% ± 13% | |
epithelial cell of proximal tubule | 7 studies | 24% ± 4% | |
vein endothelial cell | 6 studies | 22% ± 3% | |
fibroblast | 5 studies | 31% ± 13% | |
endothelial cell of vascular tree | 5 studies | 22% ± 2% | |
epithelial cell | 4 studies | 39% ± 22% | |
Mueller cell | 4 studies | 38% ± 3% | |
hepatocyte | 4 studies | 48% ± 9% | |
type II pneumocyte | 3 studies | 26% ± 13% | |
kidney loop of Henle epithelial cell | 3 studies | 25% ± 10% |
Insufficient scRNA-seq data for expression of CFI at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 22677.28 | 226 / 226 | 99% | 35.29 | 402 / 406 |
ovary | 99% | 3689.51 | 179 / 180 | 95% | 11.06 | 407 / 430 |
kidney | 100% | 9687.30 | 89 / 89 | 90% | 17.43 | 814 / 901 |
pancreas | 98% | 1990.70 | 322 / 328 | 89% | 9.89 | 159 / 178 |
thymus | 100% | 1947.89 | 651 / 653 | 78% | 8.94 | 472 / 605 |
lung | 100% | 2706.20 | 576 / 578 | 68% | 5.15 | 785 / 1155 |
uterus | 99% | 1899.08 | 168 / 170 | 52% | 4.70 | 238 / 459 |
adrenal gland | 100% | 5595.66 | 258 / 258 | 36% | 3.47 | 82 / 230 |
esophagus | 94% | 970.18 | 1357 / 1445 | 41% | 2.05 | 75 / 183 |
bladder | 95% | 1195.48 | 20 / 21 | 34% | 1.93 | 170 / 504 |
breast | 100% | 2137.07 | 458 / 459 | 26% | 1.08 | 296 / 1118 |
intestine | 88% | 936.53 | 850 / 966 | 37% | 1.89 | 194 / 527 |
prostate | 96% | 1249.20 | 236 / 245 | 17% | 0.48 | 85 / 502 |
stomach | 60% | 462.18 | 217 / 359 | 43% | 2.12 | 124 / 286 |
spleen | 100% | 3604.92 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 3439.84 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 95% | 1386.46 | 820 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 74% | 883.22 | 994 / 1335 | 0% | 0 | 0 / 0 |
skin | 30% | 168.63 | 547 / 1809 | 38% | 3.54 | 177 / 472 |
brain | 26% | 167.50 | 676 / 2642 | 39% | 2.64 | 278 / 705 |
tonsil | 0% | 0 | 0 / 0 | 29% | 0.93 | 13 / 45 |
muscle | 25% | 126.36 | 198 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.15 | 2 / 29 |
eye | 0% | 0 | 0 / 0 | 4% | 0.13 | 3 / 80 |
peripheral blood | 1% | 5.53 | 7 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006958 | Biological process | complement activation, classical pathway |
GO_0006508 | Biological process | proteolysis |
GO_0045087 | Biological process | innate immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
GO_0046872 | Molecular function | metal ion binding |
Gene name | CFI |
Protein name | Complement factor I CFI protein Complement factor I (EC 3.4.21.45) (C3B/C4B inactivator) [Cleaved into: Complement factor I heavy chain; Complement factor I light chain] |
Synonyms | IF hCG_21044 |
Description | FUNCTION: Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins . Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces . The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization . . |
Accessions | E7ETH0 ENST00000510800.1 Q8WW88 ENST00000512148.5 P05156 ENST00000394634.7 D6R9Z8 ENST00000394635.8 G3XAM2 |